Fundraising Fox

Maiabiotech

Chicago, US · 1 known investors

MAIA Biotech is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies, with a lead compound (THIO) based on a telomerase-targeting therapeutic approach. Its work spans oncology and nucleic acid-based therapeutics across multiple tumor types.

BiotechHealthtech

Founders & leadership

JH
Jeffrey HimmelreichHead of Finance
SG
Sergei GryaznovChief Scientific Officer
JC
Jeffrey C HimmelreichHead of Finance
SM
Sergei M. GryaznovChief Scientific Officer
JC
Jeffrey C. HimmelreichHead of Finance
VV
Vlad VitocChief Executive Officer and Chairman
SM
Steven M ChaoukiNamed on SEC filing
NY
Ngar Yee LouieNamed on SEC filing

Board

CL
Cristian LuputBoard director
JT
Jean-Manasse TheageneBoard director
RG
Ramiro GuerreroBoard director
SC
Steven ChaoukiBoard director

Investors · 1

Checkmate Capital Group LLCPasadena

Reported raises · per SEC filings

Form D private placements

$19.6M disclosed across 7 rounds · 2023–2025

▶$1.5MraisedJan 2026 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sergei GryaznovExecutive Officer
  • Jean-Manasse TheageneDirector
  • Ramiro GuerreroDirector
  • Stan SmithDirector
  • Cristian LuputDirector
  • Vlad VitocExecutive Officer, Director
  • Jeffrey HimmelreichExecutive Officer, Director
  • Steven ChaoukiDirector
  • Louie Ngar YeeDirector
Offering amount
$2M
Amount sold
$1.5M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedOct 2025 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Louie Ngar YeeDirector
  • Steven ChaoukiDirector
  • Stan SmithDirector
  • Sergei GryaznovExecutive Officer
  • Jeffrey HimmelreichExecutive Officer
  • Vlad VitocExecutive Officer, Director
  • Ramiro GuerreroDirector
  • Jean-Manasse TheageneDirector
  • Cristian LuputDirector
Offering amount
$7M
Amount sold
$3M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$695KraisedJun 2025 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ramiro GuerreroDirector
  • Jean-Manasse TheageneDirector
  • Louie Ngar YeeDirector
  • Vlad VitocExecutive Officer, Director
  • Cristian LuputDirector
  • Jeffrey HimmelreichExecutive Officer
  • Steven ChaoukiDirector
  • Stan SmithDirector
  • Sergei GryaznovExecutive Officer
Offering amount
$8M
Amount sold
$695K
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedMar 2025 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cristian LuputDirector
  • Jeffrey HimmelreichExecutive Officer
  • Stan SmithDirector
  • Vlad VitocExecutive Officer, Director
  • Ramiro GuerreroDirector
  • Steven ChaoukiDirector
  • Louie Ngar YeeDirector
  • Sergei GryaznovExecutive Officer
  • Jean-Manasse TheageneDirector
Offering amount
$5.9M
Amount sold
$4.1M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedNov 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cristian LuputDirector
  • Jean-Manasse TheageneDirector
  • Jeffrey HimmelreichExecutive Officer
  • Ramiro GuerreroDirector
  • Steven ChaoukiDirector
  • Sergei GryaznovExecutive Officer
  • Vlad VitocExecutive Officer, Director
  • Stan SmithDirector
  • Louie Ngar YeeDirector
Offering amount
$15.5M
Amount sold
$2.4M
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedMar 2024 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey HimmelreichExecutive Officer
  • Stan V. SmithDirector
  • Cristian LuputDirector
  • Steven ChaoukiDirector
  • Sergei GryaznovExecutive Officer
  • Ngar Yee LouieDirector
  • Ramiro GuerreroDirector
  • Vlad VitocExecutive Officer, Director
  • Jean-Manasse TheageneDirector
Offering amount
$5.7M
Amount sold
$2.9M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.9MraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cristian LuputDirector
  • Stan SmithDirector
  • Vlad VitocExecutive Officer, Director
  • Jeffrey C HimmelreichExecutive Officer
  • Ramiro GuerreroDirector
  • Sergei GryaznovExecutive Officer
  • Steven M ChaoukiDirector
  • Ngar Yee LouieDirector
  • Jean-Manasse TheageneDirector
Offering amount
$4.9M
Amount sold
$4.9M
Sales commissions
$280K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 7

by search overlap
Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood26 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public26 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits22 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Kraken21 shared keywordsKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
TipRanks19 shared keywordsFinancial analysis and stock research platform.

Companies competing with Maiabiotech for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Maiabiotech do?
MAIA Biotech is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies, with a lead compound (THIO) based on a telomerase-targeting therapeutic approach. Its work spans oncology and nucleic acid-based therapeutics across multiple tumor types.
Who are Maiabiotech's investors?
Maiabiotech's investors include Checkmate Capital Group LLC.
How much funding has Maiabiotech raised?
Maiabiotech has disclosed $19.6M raised across 7 rounds.
Where is Maiabiotech headquartered?
Maiabiotech is headquartered in Chicago, US.